|
1
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pilleron S, Cabasag CJ, Ferlay J, Bray F,
Luciani S, Almonte M and Piñeros M: Cervical cancer burden in Latin
America and the Caribbean: Where are we? Int J Cancer.
147:1638–1648. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bhatla N, Aoki D, Sharma DN and
Sankaranarayanan R: Cancer of the cervix uteri. Int J Gynaecol
Obstet. 143 (Suppl 2):S22–S36. 2018. View Article : Google Scholar
|
|
5
|
Fernandez-Retana J, Lasa-Gonsebatt F,
Lopez-Urrutia E, Coronel-Martínez J, Cantu De Leon D,
Jacobo-Herrera N, Peralta-Zaragoza O, Perez-Montiel D,
Reynoso-Noveron N, Vazquez-Romo R and Perez-Plasencia C: Transcript
profiling distinguishes complete treatment responders with locally
advanced cervical cancer. Transl Oncol. 8:77–84. 2015. View Article : Google Scholar
|
|
6
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE,
Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of
four cisplatin-containing doublet combinations in stage IVB,
recurrent, or persistent cervical carcinoma: A gynecologic oncology
group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar
|
|
7
|
Rajkumar T, Vijayalakshmi N, Sabitha K,
Shirley S, Selvaluxmy G, Bose MV and Nambaru L: A 7 gene expression
score predicts for radiation response in cancer cervix. BMC Cancer.
9:3652009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Yang S, Wang K, Lu J, Bao X, Wang
R, Qiu Y, Wang T and Yu H: Cellular senescence and cancer: Focusing
on traditional Chinese medicine and natural products. Cell Prolif.
53:e128942020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liao YH, Li CI, Lin CC, Lin JG, Chiang JH
and Li TC: Traditional Chinese medicine as adjunctive therapy
improves the long-term survival of lung cancer patients. J Cancer
Res Clin. 143:2425–2435. 2017. View Article : Google Scholar
|
|
10
|
Wang F, Yao X, Zhang Y and Tang J:
Synthesis, biological function and evaluation of shikonin in cancer
therapy. Fitoterapia. 134:329–339. 2019. View Article : Google Scholar
|
|
11
|
Boulos JC, Rahama M, Hegazy MF and Efferth
T: Shikonin derivatives for cancer prevention and therapy. Cancer
Lett. 459:248–267. 2019. View Article : Google Scholar
|
|
12
|
Hsieh YS, Liao CH, Chen WS, Pai JT and
Weng MS: Shikonin inhibited migration and invasion of human lung
cancer cells via suppression of c-met-mediated
epithelial-to-mesenchymal transition. J Cell Biochem.
118:4639–4651. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia H, Tang C, Gui H, Wang X, Qi J, Wang X
and Yang Y: Preparation, cellular uptake and angiogenic suppression
of shikonin-containing liposomes in vitro and in vivo. Biosci Rep.
33:e000202013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang Y, Sun B, Huang Z, Zhao DW and Zeng
Q: Shikonin inhibites migration and invasion of thyroid cancer
cells by downregulating DNMT1. Med Sci Monit. 24:661–670. 2018.
View Article : Google Scholar
|
|
15
|
Tang Q, Liu L, Zhang H, Xiao J and Hann
SS: Regulations of miR-183-5p and snail-mediated shikonin-reduced
epithelial-mesenchymal transition in cervical cancer cells. Drug
Des Devel Ther. 14:577–589. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu Z, Wu LJ, Li LH, Tashiro SI, Onodera S
and Ikejima T: Shikonin regulates HeLa cell death via caspase-3
activation and blockage of DNA synthesis. J Asian Nat Prod Res.
6:155–166. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wykosky J, Fenton T, Furnari F and Cavenee
WK: Therapeutic targeting of epidermal growth factor receptor in
human cancer: Successes and limitations. Chin J Cancer. 30:5–12.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yarden Y: The EGFR family and its ligands
in human cancer. Signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37 (Suppl 4):S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao Q, Wang N, Ren L, Tian J, Yang S and
Cheng H: miR-125a-5p post-transcriptionally suppresses GALNT7 to
inhibit proliferation and invasion in cervical cancer cells via the
EGFR/PI3K/AKT pathway. Cancer Cell Int. 20:1172020. View Article : Google Scholar
|
|
20
|
Muthusami S, Sabanayagam R, Periyasamy L,
Muruganantham B and Park WY: A review on the role of epidermal
growth factor signaling in the development, progression and
treatment of cervical cancer. Int J Biol Macromol. 194:179–187.
2022. View Article : Google Scholar
|
|
21
|
Cance WG, Kurenova E, Marlowe T and
Golubovskaya V: Disrupting the scaffold to improve focal adhesion
kinase-targeted cancer therapeutics. Sci Signal. 6:pe102013.
View Article : Google Scholar
|
|
22
|
Yoon H, Dehart JP, Murphy JM and Lim STS:
Understanding the roles of FAK in cancer: Inhibitors, genetic
models, and new insights. J Histochem Cytochem. 63:114–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou J, Yi Q and Tang L: The roles of
nuclear focal adhesion kinase (FAK) on cancer: A focused review. J
Exp Clin Cancer Res. 38:2502019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun J, Luo Q, Liu L, Yang X, Zhu S and
Song G: Salinomycin attenuates liver cancer stem cell motility by
enhancing cell stiffness and increasing F-actin formation via the
FAK-ERK1/2 signalling pathway. Toxicology. 384:1–10. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rogovskii VS: The linkage between
inflammation and immune tolerance: Interfering with inflammation in
cancer. Curr Cancer Drug Targets. 17:325–332. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu YG, Lv YX, Guo CY, Xiao ZM, Jiang QG,
Kuang H, Zhang WH and Hu P: Harmine inhibits the proliferation and
migration of glioblastoma cells via the FAK/AKT pathway. Life Sci.
270:1191122021. View Article : Google Scholar
|
|
27
|
Tang JC, Zhao J, Long F, Chen JY, Mu B,
Jiang Z, Ren Y and Yang J: Efficacy of shikonin against esophageal
cancer cells and its possible mechanisms in vitro and in vivo. J
Cancer. 9:32–40. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du W, Hao X, Yuan Z, Wang Y, Zhang X and
Liu J: Shikonin potentiates paclitaxel antitumor efficacy in
esophageal cancer cells via the apoptotic pathway. Oncol Lett.
18:3195–3201. 2019.
|
|
29
|
Wang F, Mayca Pozo F, Tian D, Geng X, Yao
X, Zhang Y and Tang J: Shikonin inhibits cancer through P21
upregulation and apoptosis induction. Front Pharmacol. 11:8612020.
View Article : Google Scholar
|
|
30
|
Bao C, Liu T, Qian L, Xiao C, Zhou X, Ai
H, Wang J, Fan W and Pan J: Shikonin inhibits migration and
invasion of triple-negative breast cancer cells by suppressing
epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway. J
Cancer. 12:76–88. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hussein HAM, Walker LR and Akula SM: KSHV
gB associated RGD interactions promote attachment of cells by
inhibiting the potential migratory signals induced by the
disintegrin-like domain. BMC Cancer. 16:1482016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang C, Luo Y, Zhong R, Law PTY, Boon SS,
Chen Z, Wong CH and Chan PKS: Role of polycyclic aromatic
hydrocarbons as a co-factor in human papillomavirus-mediated
carcinogenesis. BMC Cancer. 19:1382019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He JJ, Zhang WH, Liu SL, Chen YF, Liao CX,
Shen QQ and Hu P: Activation of β-adrenergic receptor promotes
cellular proliferation in human glioblastoma. Oncol Lett.
14:3846–3852. 2017. View Article : Google Scholar
|
|
34
|
Hu P, He J, Liu S, Wang M, Pan B and Zhang
W: β2-adrenergic receptor activation promotes the proliferation of
A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep.
36:1757–1763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar
|
|
37
|
Peng X and Guan JL: Focal adhesion kinase:
From in vitro studies to functional analyses in vivo. Curr Protein
Pept Sci. 12:52–67. 2011. View Article : Google Scholar
|
|
38
|
Song M, Bode AM, Dong Z and Lee MH: AKT as
a therapeutic target for cancer. Cancer Res. 79:1019–1031. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mancinelli R, Carpino G, Petrungaro S,
Mammola CL, Tomaipitinca L, Filippini A, Facchiano A, Ziparo E and
Giampietri C: Multifaceted roles of GSK-3 in cancer and
autophagy-related diseases. Oxid Med Cell Longev. 2017:46294952017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rao Y, Wang H, Fan L and Chen G: Silencing
MTA1 by RNAi reverses adhesion, migration and invasiveness of
cervical cancer cells (SiHa) via altered expression of p53, and
E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med
Sci. 31:1–9. 2011. View Article : Google Scholar
|
|
41
|
Guo N, Shen G, Zhang Y, Moustafa AA, Ge D
and You Z: Interleukin-17 promotes migration and invasion of human
cancer cells through upregulation of MTA1 expression. Front Oncol.
9:5462019. View Article : Google Scholar
|
|
42
|
Zhang L, Zhou J, Qin X, Huang H and Nie C:
Astragaloside IV inhibits the invasion and metastasis of SiHa
cervical cancer cells via the TGF-β1-mediated PI3K and MAPK
pathways. Oncol Rep. 41:2975–2986. 2019.PubMed/NCBI
|
|
43
|
Chen L, Wu YY, Liu P, Wang J, Wang G, Qin
J, Zhou J and Zhu J: Down-regulation of HPV18 E6, E7, or VEGF
expression attenuates malignant biological behavior of human
cervical cancer cells. Med Oncol. 28 (Suppl 1):S528–S539. 2011.
View Article : Google Scholar
|
|
44
|
Guo C, He J, Song X, Tan L, Wang M, Jiang
P, Li Y, Cao Z and Peng C: Pharmacological properties and
derivatives of shikonin-a review in recent years. Pharmacol Res.
149:1044632019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Guo XP, Zhang XY and Zhang SD: Clinical
trial on the effects of shikonin mixture on later stage lung
cancer. Zhong Xi Yi Jie He Za Zhi. 11:598–599. 5801991.(In
Chinese).
|
|
46
|
Ko H, Kim SJ, Shim SH, Chang H and Ha CH:
Shikonin induces apoptotic cell death via regulation of p53 and
Nrf2 in AGS human stomach carcinoma cells. Biomol Ther (Seoul).
24:501–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brami-Cherrier K, Gervasi N, Arsenieva D,
Walkiewicz K, Boutterin MC, Ortega A, Leonard PG, Seantier B, Gasmi
L, Bouceba T, et al: FAK dimerization controls its kinase-dependent
functions at focal adhesions. EMBO J. 33:356–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Watanabe N, Takaoka M, Sakurama K, Tomono
Y, Hatakeyama S, Ohmori O, Motoki T, Shirakawa Y, Yamatsuji T,
Haisa M, et al: Dual tyrosine kinase inhibitor for focal adhesion
kinase and insulin-like growth factor-I receptor exhibits
anticancer effect in esophageal adenocarcinoma in vitro and in
vivo. Clin Cancer Res. 14:4631–4639. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang J and Hochwald SN: The role of FAK
in tumor metabolism and therapy. Pharmacol Ther. 142:154–163. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Revathidevi S and Munirajan AK: Akt in
cancer: Mediator and more. Semin Cancer Biol. 59:80–91. 2019.
View Article : Google Scholar
|
|
51
|
Zhang X, Jiang G, Sun M, Zhou H, Miao Y,
Liang M, Wang E and Zhang Y: Cytosolic THUMPD1 promotes breast
cancer cells invasion and metastasis via the AKT-GSK3-snail
pathway. Oncotarget. 8:13357–13366. 2017. View Article : Google Scholar
|
|
52
|
Shi X, Yang J and Wei G: Ginsenoside
20(S)-Rh2 exerts anti-cancer activity through the Akt/GSK3β
signaling pathway in human cervical cancer cells. Mol Med Rep.
17:4811–4816. 2018.PubMed/NCBI
|
|
53
|
Dai J, Qian C, Su M, Chen M and Chen J:
Gastrokine-2 suppresses epithelial mesenchymal transition through
PI3K/AKT/GSK3β signaling in gastric cancer. Tumour Biol.
37:12403–12410. 2016. View Article : Google Scholar
|
|
54
|
Shan ZL, Zhong L, Xiao CL, Gan LG, Xu T,
Song H, Yang R, Li L and Liu BZ: Shikonin suppresses proliferation
and induces apoptosis in human leukemia NB4 cells through
modulation of MAPKs and c-Myc. Mol Med Rep. 16:3055–3060. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pan T, Zhang F, Li F, Gao X, Li Z, Li X
and Ren X: Shikonin blocks human lung adenocarcinoma cell migration
and invasion in the inflammatory microenvironment via the
IL-6/STAT3 signaling pathway. Oncol Rep. 44:1049–1063. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chen Y, Hu X and Yang S: Clinical
significance of focal adhesion kinase (FAK) in cervical cancer
progression and metastasis. Int J Clin Exp Pathol. 13:2586–2592.
2020.
|
|
57
|
Chuang HH, Zhen YY, Tsai YC, Chuang CH,
Hsiao M, Huang MS and Yang CJ: FAK in cancer: From mechanisms to
therapeutic strategies. Int J Mol Sci. 23:17262022. View Article : Google Scholar
|
|
58
|
Tomas A, Futter CE and Eden ER: EGF
receptor trafficking: Consequences for signaling and cancer. Trends
Cell Biol. 24:26–34. 2014. View Article : Google Scholar
|
